Androgenetic Alopecia
Conditions
Brief summary
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration
Detailed description
A total of 40 subjects will be evaluated with 32 subjects randomized to receive active drug and 8 subjects randomized to receive placebo in a double-blind fashion (ten subjects in each dose cohort with two subjects randomized to placebo for total of four dose cohorts).Subjects were to be assigned to 1 of the 4 dose levels, 3 mg. 12 mg, 48 mg and 96 mg of KX-826 or placebo to match the active product, administered as a topical application.
Interventions
DRUGKX0826
AR antagonist
OTHERPlacebo
Placebo of KX-826
Sponsors
Suzhou Kintor Pharmaceutical Inc,
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Are capable of giving informed consent and complying with study procedures; 2. Are males between the ages of 18 and 60 years, inclusive; 3. Have a clinical diagnosis of AGA; 4. Considered healthy by the PI, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs; 5. Have normal renal and hepatic function as determined by the screening laboratory results; 6. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening; 7. Body mass index (BMI) of 19.0 to 35.0 kg/m2 inclusive and body weight not less than 50 kg; 8. Willing and able to adhere to study restrictions and to be confined at the clinical research center.
Exclusion criteria
1. Clinically significant history of gastrointestinal (GI), cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity; 2. Any visible skin disease, damage or condition at the application site which, in the opinion of the investigator, could compromise subject safety and/or interfere with the evaluation of the test site reaction; 3. Subject has any dermatological disorders of the scalp; 4. Subject has a history of hair transplants, hair weaves; 5. Subject has hypersensitivity to previously prescribed minoxidil or finasteride; 6. Known or suspected malignancy; 7. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBs Ag), or hepatitis C (HCV) antibody; 8. A hospital admission or major surgery within 30 days prior to screening; 9. Participation in any other investigational drug trial within 30 days prior to screening; 10. A history of prescription drug abuse, or illicit drug use within 6 months prior to screening; 11. A history of alcohol abuse according to medical history within 6 months prior to screening; 12. A positive screen for alcohol or drugs of abuse; 13. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening; 14. Use of prescription or over the counter (OTC) medications, and herbal (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at \< 3g/day was permitted until 24 hours prior to dosing); 15. An unwillingness of male participants to use appropriate contraceptive measures if engaging in sexual intercourse with a female partner of childbearing potential. Appropriate measures include use of a condom and spermicide and, for female partners, use of an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, progesterone subdermal implants, or a tubal ligation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-emergent adverse events (TEAE) by skin irritation assessments | 3 days | Skin irritation assessments will be performed during the treatment period. The dermal response score will be based on a visual irritation scale (0-7) that rates the degree of erythema, edema and other signs of cutaneous irritation. |
| Incidence of treatment-emergent adverse events (TEAE) by vital signs measurements | 3 days | vital signs (including blood pressure, pulse rate, respiratory rate and oral temperatures) |
| Incidence of treatment-emergent adverse events (TEAE) by ECG assessment | 3 days | 12-lead ECG |
| Incidence of treatment-emergent adverse events (TEAE) by clinical lab tests | 3 days | hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, with differential), blood chemistry (BUN, creatinine, total bilirubin, alkaline phosphatase, AST, ALT, GGT, LDH, glucose, albumin, total protein, bicarbonate, phosphate, sodium, potassium, chloride, calcium, total cholesterol, uric acid) and urinalysis (pH, specific gravity, protein, glucose, ketones, bilirubin, blood, nitrites, leukocytes, urobilinogen, microscopic urine analysis on abnormal findings) |
| Incidence of study drug related TEAEs | 3 days | incidence of study drug related TEAEs (possibly, probably or definitely) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Apparent total systemic clearance, calculated as Dose/AUCinf(Cl/F) | 48 hours | Pharmacokinetics |
| AUC from time 0 and extrapolated to infinite time, total exposure(AUCinf) | 48 hours | Pharmacokinetics |
| elimination rate constant（Kel） | 48 hours | Pharmacokinetics |
| Apparent volume of distribution(Vd/F) | 48 hours | Pharmacokinetics |
| AUC from time 0 to the last non-zero concentration(AUClast) | 48 hours | Pharmacokinetics |
| Maximum observed concentration (Cmax) | 48 hours | Pharmacokinetics |
| Time at which Cmax was first observed(Tmax) | 48 hours | Pharmacokinetics |
| half life（T½） | 48 hours | Pharmacokinetics |
Countries
United States
Outcome results
None listed